Results: DNL

Search articles by EPIC code
EPIC DNL
views

Diurnal – CEO ‘step down to pursue other business opportunities with group poised for its next stage of growth’. Really?...

“Directorate Change and Management Updates” announcement from Diurnal Group (DNL) includes that David Bevan, with over 30 years of broad base expertise in the industry, has been promoted to a newly created role of Chief Business Officer. Though, with shares in the group currently down more than 4.5% to 15.25p, what else does the announcement include?...

EPIC DNL
views

Diurnal – interims noting revenue growth, so why the share price slump?...

Hormonal diseases-targeting pharmaceutical group Diurnal (DNL) has announced results for its half-year ended 31st December 2021 including “Alkindi product sales (including royalties) for the period increased to £1.74m, representing year-on-year growth of 46%… Efmody initial product sales for the period of £0.39m were in line with the company's expectations”. So why a share price response to below 18p, more than 46% lower?!...

Page 1 of 1 (5 articles)
Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments